Clinical Trial Update: Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluating cabozantinib-s-malate in combination with vemurafenib for metastatic or unresectable solid tumors and melanoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cabozantinib S-Malate (cabozantinib)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IIIA Melanoma | Phase 1 | Status: TERMINATED